SCHEMBL5873057

SCHEMBL5873057

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)Nc2cccnc2)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.47
CYP11B2 P19099 3/20 0.46
CYP11B1 P15538 1/20 0.46
BRAF P15056 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
TDP1 Q9NUW8 1/20 0.42
IDO1 P14902 1/20 0.42
NAMPT P43490 4/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HTT P42858 1/20 0.42
MAP2K2 P36507 1/20 0.42
MAP2K1 Q02750 1/20 0.42
SGMS2 Q8NHU3 1/20 0.42
TP53 P04637 1/20 0.41
CSF1R P07333 1/20 0.41
KIT P10721 1/20 0.41
KDR P35968 1/20 0.41
MAPK14 Q16539 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5873059 0.96 SORT1 (0.47) SORT1CYP11B2CYP11B1BRAFMEN1
SCHEMBL5872838 0.84 USP2 (0.50) SORT1MEN1KMT2ATDP1HSD17B10
SCHEMBL5872778 0.84 KCNQ3 (0.46) SORT1MEN1KMT2ATDP1IDO1
SCHEMBL5872850 0.81 MAP2K1 (0.56) MEN1KMT2ATDP1IDO1MAP2K2
SCHEMBL5872840 0.81 USP2 (0.50) SORT1MEN1KMT2ATDP1HSD17B10
SCHEMBL5872858 0.81 MAP2K1 (0.51) MEN1KMT2ATDP1IDO1MAP2K2
SCHEMBL5872780 0.80 KCNQ3 (0.46) SORT1MEN1KMT2ATDP1IDO1
SCHEMBL5872912 0.79 NPC1 (0.49) MEN1KMT2ATDP1IDO1HSD17B10
SCHEMBL5873050 0.79 AURKA (0.45) MEN1KMT2ATDP1IDO1ALDH1A1
SCHEMBL24849049 0.79 MAP2K1 (0.56) MEN1KMT2ATDP1IDO1MAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed
EP-1339702-A1 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEK INHIBITORS WARNER-LAMBERT COMPANY (US) 2003-09-03 EP disclosed
WO-2001068619-A1 5-AMIDE SUBSTITUTED DIARYLAMINES AS MEX INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 SORT1 4712/4885CYP11B2 864/4885CYP11B1 454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.